Tag: life sciences
-
Trial to Test Low-Dose Psilocybin for Mental Distress
A developer of mental health therapies from psychedelic compounds says it received FDA clearance for a clinical trial testing low doses of psilocybin.
-
HPV Vaccine Generates Immune Responses in Trial
Early results from a clinical trial show a vaccine for the human papillomavirus is safe and invokes immune responses in women with low-grade cervical lesions.
-
Standard Electronic Biomarkers Validated for Schizophrenia
A new study validates standard electronic instrument measures of healthy individuals and people with schizophrenia to enable reliable clinical trials for treating the disease.
-
Post-Surgical Fluid Cancer Analytics Company Gains $8M
A start-up company developing liquid biopsies for diagnosing cancer by analyzing fluids drained from a patient after surgery is raising $8 million in seed funds.
-
Trial Shows Electronic Dressing Stops Biofilm Infections in Burns
Findings from a clinical trial show a dressing for burns with an electric current prevents formation of bacterial films, reducing risks of infections.
-
Remote Monitoring Shown to Reduce COPD Hospital Visits
A study of people with COPD shows patients using a wearable electronic device to report health status have fewer unplanned hospital visits than before using the device.
-
Gene Therapy Shown to Build Knee Cartilage
Findings from research with lab animals shows a single gene therapy injection delivered with a benign virus helps build new knee cartilage cells and tissue.
-
PCORI Funds Personal Dialysis Model Assessment
A team from an academic medical center and research institute are evaluating a personalized dialysis model for people with kidney disease, but with still some kidney functions.
-
A.I. Shown to Enhance Diagnostics in Liquid Biopsies
A new analysis shows machine learning algorithms can provide more diagnostic details in liquid biopsies, blood tests to detect and track solid tumor cancers.
-
Fox Foundation Funds New Genetic Variation Targets for Parkinson’s
A Parkinson’s disease organization is giving a grant to a neurodegenerative therapies developer that targets new groups of underlying disease-causing genetic changes.